

2-stage design is utilized. Target accrual is 22 patients in the first stage; 13 or more patients without progressive disease within 6 months is required to proceed to second stage.

Results We report the results from the first stage. Median age was 56 years old, high grade serous and most of the patients (90.9%) had high-grade serous carcinoma. Of the 22 patients from the first stage, 9 had progressive disease within 6 months (6-month PFS rate 66.5%, 95% CI 48.9–90.2%). The efficacy boundary to proceed to the second stage was met. No grade 4 or 5 treatment-related adverse events (TRAEs) were reported, and no TRAEs leading to treatment discontinuation.

Conclusion/Implications Our findings indicate encouraging safety and activity of niraparib + bevacizumab as a maintenance therapy in platinum-sensitive ovarian cancer patients who were previously treated with a PARPi.

PRO55/#936

INFLUENCE OF SPATIAL TUMOUR HETEROGENEITY ON HOMOLOGOUS RECOMBINATION DEFICIENCY SCORES FOR HIGH GRADE SEROUS OVARIAN CANCER PATIENTS

¹Christina Fotopoulou*, ²Elizabeth Christie, ¹Marc Lorentzen, ¹Maiqi Liu, ¹Edward Curry, ¹Chun Hei Kwok, ¹Katherine Nixon, ¹Jennifer Ploski, ¹James Clark, ¹Iain Mcneish, ¹Jonathan Krell, ¹Paula Cunnea. ¹Imperial College London, Surgery and Cancer, London, UK; ²Peter MacCallum Cancer Centre, Department of Oncology, Melbourne, UK

10.1136/ijgc-2023-IGCS.96

Introduction Extensive genomic instability and heterogeneity are characteristics of high-grade serous ovarian cancer (HGSOC), with deficiency in homologous recombination (HR) repair has been reported for approximately 50% of HGSOC patients. Testing tumours for HR-deficiency (HRD) status is now a clinically applicable test, with a HR score of >42 suggestive of HRD and thus, platinum or PARP-inhibitor sensitivity in HGSOC. We aimed to determine the influence of spatial heterogeneity on HR scores in disseminated HGSOC.

Methods An algorithm detecting genomic scar HR scores was applied to genomic data from three cohorts of multi-site tumour samples – in-house Hammersmith hospital (HH) 45 patients n=5 tumours per patient; GSE38787 (n=24 patients) and GSE40546 (n=14 patients). A HR score is an unweighted sum of three independent measures of genomic instability: loss

of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transition (LST). A cut-off >42 denotes HR-deficient.

Results Heterogeneity in tumour HR scores were detected in each cohort with patients presenting with either all HRD tumours, all HRP tumours or mixed HR scores, showing both HRD and HR-Proficient (HRP) tumour scores: HH (22%); GSE38787 (17%); and GSE40546 (28%). Within the HH cohort, survival analysis revealed that patients with all HRP tumours and mixed HR status had worse survival (progression-free survival p=0.0052; overall-survival p=0.00092) than patients with all HRD tumours.

Conclusion/Implications Our data demonstrating differences in HRD/HRP scores proposes that HR status may vary across disseminated HGSOC. Thus, implying that testing a single tumour biopsy may not accurately portray HGSOC tumour biology and could incorrectly guide clinical decision-making.

PRO56/#32

CLINICAL CHARACTERISTICS AND ONCOLOGICAL OUTCOMES OF RECURRENT ADULT GRANULOSA CELL TUMOR OF OVARY: A RETROSPECTIVE STUDY OF SEVENTY PATIENTS

¹Yu Gu*, ²Yang Xiang. ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Obstetrics and Gynecology, Beijing, China; ²Peking Union Medical College Hospital, Department of Obstetrics and Gynecology, Beijing, China

10.1136/ijgc-2023-IGCS.97

Introduction To describe the clinicopathological characteristics of recurrent adult granulosa cell tumor (AGCT) and identify the risk factors for recurrence.

Methods Seventy recurrent AGCT patients between 2000–2020 were retrospectively reviewed (figure 1). The primary outcomes were progression free survival after first recurrence (PFS-R), overall survival after first recurrence (OS-R) and recurrence frequency. The Kaplan-Meier (KM) analysis, Cox proportional hazard analysis, and the Prentice, Williams and Peterson counting process (PWP-CP) model were adopted.

Results The 5-year PFS-R was 29.3%, and the 5-year OS-R was 94.9%. KM analysis demonstrated that patients with distant recurrence and PFS1 ≤60 months had worse PFS-R (P<0.05), and patients with PFS-R ≤ 33 months had worse

Abstract PR056/#32 Table 1 Univariate and multivariate analysis of PFS-R and OS-R

	PFS-R				OS-R			
	Univariate		Multivariate		Univariate		Multivariate	
	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)
Age ≤46	0.113	1.618 (0.893, 2.931)			0.145	0.405(0.120, 1.366)		
Operation approach (TA)	0.966	0.982 (0.415, 2.322)			0.205	0.353(0.071, 1.769)		
Adjuvant chemotherapy	0.636	0.866 (0.477, 1.572)			0.787	0.846(0.252, 2.838)		
Tumor size(≤7.1cm)	0.339	0.740 (0.399, 1.371)			0.608	0.674(0.149, 3.045)		
Recurrence site(single)	0.079	0.551 (0.284, 1.071)			0.072	0.145(0.018, 1.186)	0.056	0.116 (0.013, 1.059)
Recurrence site(local)	0.018	0.466 (0.247, 0.876)	0.027	0.488(0.259, 0.922)	0.295	0.519(0.152, 1.773)		
R0 (first recurrence surgery)	0.179	0.642 (0.336, 1.226)			0.269	0.510(0.154, 1.684)		
PFS1 ≤60 months	0.017	2.007 (1.130, 3.565)	0.028	1.911(1.073, 3.402)	0.079	3.446(0.868, 13.683)	0.258	2.222 (0.557, 8.862)
PFS-R ≤33months	-	-			0.023	5.156(1.249, 21.284)	0.028	5.505 (1.199, 25.259)